ZyVersa Therapeutics, Inc. (ZVSA)
(Delayed Data from NSDQ)
$2.47 USD
+0.09 (3.78%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $2.43 -0.04 (-1.62%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Income Statements
Fiscal Year end for ZyVersa Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 108 | 14 | 8 | 0 | 0 |
Income After Depreciation & Amortization | -108 | -14 | -8 | 0 | 0 |
Non-Operating Income | 0 | -1 | 0 | NA | NA |
Interest Expense | 0 | 0 | 1 | NA | NA |
Pretax Income | -108 | -15 | -8 | NA | NA |
Income Taxes | -9 | -1 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -98 | -14 | -8 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -98 | -14 | -8 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -96 | -14 | -7 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 12 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -108 | -14 | -8 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.10 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -967.70 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -1,089.70 | -937.06 | NA | NA | NA |
Fiscal Year end for ZyVersa Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.75 | 2.82 | 13.94 | 2.90 | 86.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.75 | -2.82 | -13.94 | -2.90 | -86.33 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.75 | -2.83 | -13.93 | -2.90 | -86.33 |
Income Taxes | 0.01 | 0.00 | -0.60 | 0.00 | -7.81 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.76 | -2.83 | -13.34 | -2.90 | -78.51 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.76 | -2.83 | -13.34 | -2.90 | -78.51 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 0.84 | 0.62 | NA | 0.09 | 0.05 |
Diluted EPS Before Non-Recurring Items | -3.31 | -4.53 | NA | -31.47 | -1,458.04 |
Diluted Net EPS (GAAP) | -3.31 | -4.53 | 770.44 | -31.47 | -1,692.31 |